# ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

> **NCT03122262** · PHASE3 · COMPLETED · sponsor: **Professor Francois Venter** · enrollment: 1110 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Dolutegravir
- **DRUG:** Tenofovir Alafenamide
- **DRUG:** Truvada
- **DRUG:** Atripla

## Key facts

- **NCT ID:** NCT03122262
- **Lead sponsor:** Professor Francois Venter
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-16
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-07-29
- **Target enrollment:** 1110 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03122262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03122262, "ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03122262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*